Literature DB >> 27539721

Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study.

Johan Ljungqvist1, Henrik Zetterberg2,3,4, Marios Mitsis5, Kaj Blennow2,3, Thomas Skoglund1.   

Abstract

Diffuse axonal injury (DAI) is an important cause of morbidity in patients with traumatic brain injury (TBI). There is currently no simple and reliable technique for early identification of patients with DAI, or to prognosticate long-term outcome in this patient group. In the present study, we examined acute serum concentrations of neurofilament light (NFL) in nine patients with severe TBI and DAI using a novel ultrasensitive single molecule array (Simoa) assay. The relationships between the NFL concentrations and MRI in the acute stage as well as clinical outcome and magnetic resonance diffusion tensor imaging (MR-DTI) parameters at 12 months were analyzed. We found that the mean NFL concentrations among the patients displayed a 30-fold increase compared with controls, and that NFL completely discriminated between the patients and controls. We also found a relationship between serum NFL and MR-DTI parameters, with higher NFL concentrations in patients with higher trace (R2 = 0.79) and lower fractional anisotropy (FA) (R 2 = 0.83). These results suggest that serum NFL may be a valuable blood biomarker for TBI, reflecting the severity of DAI.

Entities:  

Keywords:  DTI; MRI; TBI; axonal injury; biomarkers

Mesh:

Substances:

Year:  2016        PMID: 27539721     DOI: 10.1089/neu.2016.4496

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  36 in total

Review 1.  How to Translate Time: The Temporal Aspects of Rodent and Human Pathobiological Processes in Traumatic Brain Injury.

Authors:  Denes V Agoston; Robert Vink; Adel Helmy; Mårten Risling; David Nelson; Mayumi Prins
Journal:  J Neurotrauma       Date:  2019-03-07       Impact factor: 5.269

2.  Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports.

Authors:  Pashtun Shahim; Henrik Zetterberg; Yelverton Tegner; Kaj Blennow
Journal:  Neurology       Date:  2017-04-12       Impact factor: 9.910

3.  Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury.

Authors:  Jussi P Posti; Riikka S K Takala; Linnéa Lagerstedt; Alex M Dickens; Iftakher Hossain; Mehrbod Mohammadian; Henna Ala-Seppälä; Janek Frantzén; Mark van Gils; Peter J Hutchinson; Ari J Katila; Henna-Riikka Maanpää; David K Menon; Virginia F Newcombe; Jussi Tallus; Kevin Hrusovsky; David H Wilson; Jessica Gill; Jean-Charles Sanchez; Olli Tenovuo; Henrik Zetterberg; Kaj Blennow
Journal:  J Neurotrauma       Date:  2019-04-05       Impact factor: 5.269

Review 4.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

Review 5.  Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.

Authors:  Zahra Alirezaei; Mohammad Hossein Pourhanifeh; Sarina Borran; Majid Nejati; Hamed Mirzaei; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.590

6.  cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.

Authors:  Yo Sasaki; Thomas M Engber; Robert O Hughes; Matthew D Figley; Tong Wu; Todd Bosanac; Rajesh Devraj; Jeffrey Milbrandt; Raul Krauss; Aaron DiAntonio
Journal:  Exp Neurol       Date:  2020-02-19       Impact factor: 5.330

7.  Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.

Authors:  Jessica Gill; Lawrence Latour; Ramon Diaz-Arrastia; Vida Motamedi; Christine Turtzo; Pashtun Shahim; Stefania Mondello; Christina DeVoto; Eliseo Veras; David Hanlon; Linan Song; Andreas Jeromin
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

8.  Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI.

Authors:  Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Vindhya Ekanayake; Sara M Lippa; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Henrik Zetterberg; Kaj Blennow; Jessica M Gill; David L Brody; Leighton Chan
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

9.  Neurofilament light as a biomarker in traumatic brain injury.

Authors:  Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Jessica M Gill; David L Brody; Henrik Zetterberg; Kaj Blennow; Leighton Chan
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

10.  Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Authors:  Ruchira M Jha; Stefania Mondello; Helen M Bramlett; C Edward Dixon; Deborah A Shear; W Dalton Dietrich; Kevin K W Wang; Zhihui Yang; Ronald L Hayes; Samuel M Poloyac; Philip E Empey; Audrey D Lafrenaye; Hong Q Yan; Shaun W Carlson; John T Povlishock; Janice S Gilsdorf; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2020-12-18       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.